AtaiBeckley's EMP-01 reduced social anxiety in 49% of patients with a good safety profile, showing promise for a new treatment.

AtaiBeckley Inc. reported positive topline results from a Phase 2a trial of its oral R-MDMA treatment, EMP-01, for social anxiety disorder, showing a favorable safety profile and meaningful symptom improvement in 49% of participants. The double-blind, placebo-controlled trial met its primary safety goal and demonstrated promising signals in reducing anxiety symptoms, measured by the Liebowitz Social Anxiety Scale. The company plans to present more detailed data at upcoming scientific conferences. The results, which come amid a lack of new SAD treatments in over two decades, contributed to a 5% rise in the company’s stock in premarket trading.